vida: extract claims from 2026-04-29-lilly-employer-connect-not-revolutionary-dte-limits
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
- Source: inbox/queue/2026-04-29-lilly-employer-connect-not-revolutionary-dte-limits.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
This commit is contained in:
parent
dfdc9b20ea
commit
5880b8f037
2 changed files with 11 additions and 1 deletions
|
|
@ -46,3 +46,10 @@ Eli Lilly Employer Connect launched March 5, 2026 at $449/dose with partnerships
|
|||
**Source:** HR Brew/PR Newswire Q4 2025-Q1 2026 DTE announcements
|
||||
|
||||
Both major GLP-1 manufacturers (Eli Lilly via Employer Connect, Novo Nordisk via 9amHealth/Waltz Health partnerships) now operate DTE channels as of Q1 2026. Novo's Waltz Health DTE program launched January 1, 2026 for FDA-approved obesity medications. 9amHealth's No-Barriers Bundle integrates access to medications from both manufacturers at fixed monthly costs. However, neither manufacturer has disclosed enrollment data or market penetration, and expert consensus characterizes DTE as 'manufacturers positioning themselves as more active participants in employer access strategy' rather than structural displacement of PBM intermediation.
|
||||
|
||||
|
||||
## Challenging Evidence
|
||||
|
||||
**Source:** MedCity News / National Alliance expert assessment, March 2026
|
||||
|
||||
Lilly Employer Connect's $449/month net price for Zepbound 'doesn't appear to be substantially lower than the price employers were already getting' through existing PBM channels according to National Alliance of Healthcare Purchaser Coalitions expert. Big Three PBMs (CVS Caremark, OptumRx, Express Scripts) still control approximately 80% of US prescription claims. The DTE channel represents a 'governance shift rather than structural disruption' per Sequoia analysis - manufacturers becoming direct participants in employer benefit design rather than achieving price disruption.
|
||||
|
|
|
|||
|
|
@ -7,10 +7,13 @@ date: 2026-03-05
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: article
|
||||
status: unprocessed
|
||||
status: processed
|
||||
processed_by: vida
|
||||
processed_date: 2026-04-29
|
||||
priority: medium
|
||||
tags: [GLP-1, direct-to-employer, DTE, PBM, Lilly, employer-coverage, market-competition]
|
||||
intake_tier: research-task
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
Loading…
Reference in a new issue